» Articles » PMID: 2454375

Pharmacokinetics and Disposition of Carvedilol in Humans

Overview
Date 1987 Jan 1
PMID 2454375
Citations 33
Authors
Affiliations
Soon will be listed here.
Abstract

Pharmacokinetics of carvedilol (C) have been studied in healthy volunteers after a single i.v. and oral administration, and the metabolic disposition after oral administration of 14C-labeled drug. C demonstrates dose-linear behavior. The absolute bioavailability reaches 24% probably due to a first-pass effect. After a 50 mg oral dose, maximum concentrations of 66 micrograms/l are achieved within 1.2 h. C is extensively distributed to the tissues (Vz = 132 l) and eliminated primarily by hepatic metabolism (total clearance 590 ml/min, renal clearance 4 ml/min). Because of the longer half-life of 6.4 h after oral administration in contrast to 2.4 h after i.v. administration, C is assumed to be absorption dependent since no sustained-release formulation was used. The half-life of radioactivity in plasma is 39 h; 16% of C is excreted in urine in the form of metabolites and only 0.3% unchanged. The urinary metabolites consist of carvedilol glucuronide (5.2% of the dose), cleavage products of the beta-blocking side chain (2.1%), and ring-hydroxylated forms (2.9%). Sixty percent of the dose is recovered in the feces. A demethylated product of C exhibits only minor beta-blocking activity. This metabolite is detected in plasma in concentrations ten times lower than the parent compound.

Citing Articles

UHPLC Enantiomer Resolution for the ɑ/β-Adrenoceptor Antagonist -Carvedilol and Its Major Active Metabolites on Chiralpak IB N-5.

Samir L, Hanafi R, El Deeb S, Spahn-Langguth H Molecules. 2022; 27(15).

PMID: 35956942 PMC: 9370150. DOI: 10.3390/molecules27154998.


A simple LC-MS/MS method for pharmacokinetic study of carvedilol and 4/-hydroxyphenyl carvedilol at a low dose.

Eiamart W, Prompila N, Jumroen Y, Sayankuldilok N, Chariyavilaskul P, Wittayalertpanya S Res Pharm Sci. 2022; 17(3):231-241.

PMID: 35531138 PMC: 9075024. DOI: 10.4103/1735-5362.343077.


Extracorporeal treatment for poisoning to beta-adrenergic antagonists: systematic review and recommendations from the EXTRIP workgroup.

Bouchard J, Shepherd G, Hoffman R, Gosselin S, Roberts D, Li Y Crit Care. 2021; 25(1):201.

PMID: 34112223 PMC: 8194226. DOI: 10.1186/s13054-021-03585-7.


Influence of Polymorphism on the Pharmacokinetic/Pharmacodynamic Characteristics of Carvedilol in Healthy Korean Volunteers.

Jung E, Ryu S, Park Z, Lee J, Yi J, Seo D J Korean Med Sci. 2018; 33(27):e182.

PMID: 29962926 PMC: 6021360. DOI: 10.3346/jkms.2018.33.e182.


Optimizing the Clinical Use of Carvedilol in Liver Cirrhosis Using a Physiologically Based Pharmacokinetic Modeling Approach.

Rasool M, Khalil F, Laer S Eur J Drug Metab Pharmacokinet. 2016; 42(3):383-396.

PMID: 27313074 DOI: 10.1007/s13318-016-0353-2.